RU2019102757A - Производные этинила - Google Patents
Производные этинила Download PDFInfo
- Publication number
- RU2019102757A RU2019102757A RU2019102757A RU2019102757A RU2019102757A RU 2019102757 A RU2019102757 A RU 2019102757A RU 2019102757 A RU2019102757 A RU 2019102757A RU 2019102757 A RU2019102757 A RU 2019102757A RU 2019102757 A RU2019102757 A RU 2019102757A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- neuroprotection
- autism
- obsessive
- Prior art date
Links
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 title 1
- XEHVFKKSDRMODV-UHFFFAOYSA-N ethynyl Chemical class C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 3
- 208000020706 Autistic disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000004112 neuroprotection Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 230000008673 vomiting Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Соединение формул IA и IB
или его фармацевтически приемлемая соль или кислотно-аддитивная соль, рацемическая смесь, или его соответствующий энантиомер и/или оптический изомер и/или стереоизомер.
2. Способ получения соединения формул IA или IB, как определено в п. 1, который содержит
алкилирование соединения формулы
с помощью этилйодида и разделение изомеров на соединение формул
или, в случае необходимости, конвертирование полученных соединений в их фармацевтически приемлемые соли.
3. Соединение формулы IA или IB по п. 1 для применения в качестве терапевтически активного вещества.
4. Соединение формулы IA или IB по п. 1 для применения в лечении болезни Паркинсона, тревоги, рвоты, обсессивно-компульсивного расстройства, аутизма, нейропротекции, рака, депрессии и диабета 2 типа.
5. Фармацевтическая композиция, содержащая соединение формулы IA или IB по п. 1 и фармацевтически приемлемые эксципиенты.
6. Применение соединения формулы IA или IB по п. 1 для получения лекарственного средства для лечения болезни Паркинсона, тревоги, рвоты, обсессивно-компульсивного расстройства, аутизма, нейропротекции, рака, депрессии и диабета 2 типа.
7. Способ лечения болезни Паркинсона, тревоги, рвоты, обсессивно-компульсивного расстройства, аутизма, нейропротекции, рака, депрессии и диабета 2 типа, при котором вводят эффективное количество соединения формулы IA или IB по п. 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16179837 | 2016-07-18 | ||
| EP16179837.6 | 2016-07-18 | ||
| PCT/EP2017/067495 WO2018015235A1 (en) | 2016-07-18 | 2017-07-12 | Ethynyl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019102757A true RU2019102757A (ru) | 2020-08-18 |
| RU2019102757A3 RU2019102757A3 (ru) | 2020-08-18 |
| RU2745068C2 RU2745068C2 (ru) | 2021-03-18 |
Family
ID=56418435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019102757A RU2745068C2 (ru) | 2016-07-18 | 2017-07-12 | Производные этинила |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20190144458A1 (ru) |
| EP (1) | EP3484889B1 (ru) |
| JP (1) | JP6936305B2 (ru) |
| KR (1) | KR20190026805A (ru) |
| CN (1) | CN109476671B (ru) |
| AR (1) | AR109075A1 (ru) |
| AU (1) | AU2017299083B2 (ru) |
| BR (1) | BR112019000314A2 (ru) |
| CA (1) | CA3030788A1 (ru) |
| CL (1) | CL2019000045A1 (ru) |
| CO (1) | CO2018013824A2 (ru) |
| CR (1) | CR20190014A (ru) |
| DK (1) | DK3484889T3 (ru) |
| ES (1) | ES2826389T3 (ru) |
| HR (1) | HRP20201615T1 (ru) |
| HU (1) | HUE051006T2 (ru) |
| IL (1) | IL263884A (ru) |
| LT (1) | LT3484889T (ru) |
| MA (1) | MA45665B1 (ru) |
| MX (1) | MX376249B (ru) |
| PE (1) | PE20190382A1 (ru) |
| PH (1) | PH12019500119A1 (ru) |
| PL (1) | PL3484889T3 (ru) |
| PT (1) | PT3484889T (ru) |
| RS (1) | RS60908B1 (ru) |
| RU (1) | RU2745068C2 (ru) |
| SG (1) | SG11201811829QA (ru) |
| SI (1) | SI3484889T1 (ru) |
| TW (1) | TWI729169B (ru) |
| WO (1) | WO2018015235A1 (ru) |
| ZA (1) | ZA201900113B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX374409B (es) | 2015-07-15 | 2025-03-04 | Hoffmann La Roche | Derivados de etinilo como moduladores del receptor de glutamato metabotrópico. |
| CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
| US11515154B2 (en) * | 2020-10-27 | 2022-11-29 | Applied Materials, Inc. | Selective deposition of a passivation film |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060116366A1 (en) * | 2002-12-04 | 2006-06-01 | Parmee Emma R | Spirocyclic ureas, compositions containing such compounds and methods of use |
| JP5567268B2 (ja) | 2005-05-24 | 2014-08-06 | メルク セローノ ソシエテ アノニム | Ｃｒｔｈ２の調節剤としての三環系スピロ誘導体 |
| US7998961B2 (en) | 2006-08-31 | 2011-08-16 | Schering Corporation | Hydantoin derivatives useful as antibacterial agents |
| MX2009013169A (es) | 2007-06-03 | 2010-04-30 | Univ Vanderbilt | Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos. |
| CA2773038A1 (en) | 2009-09-04 | 2011-03-10 | P. Jeffrey Conn | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| US8957213B2 (en) | 2011-04-26 | 2015-02-17 | Hoffman-La Roche Inc. | Ethynyl compounds |
| MX2013011107A (es) | 2011-04-26 | 2013-10-17 | Hoffmann La Roche | Derivados de pirazolidin-3-ona. |
| WO2012162635A1 (en) | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Metabotropic glutamate receptors 5 modulators and methods of use thereof |
| AU2012278976B2 (en) * | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110995C2 (uk) | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| EP2875000B1 (en) | 2012-07-17 | 2016-09-21 | F. Hoffmann-La Roche AG | Arylethynyl derivatives |
| WO2014060394A1 (en) | 2012-10-18 | 2014-04-24 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mglur5 receptor activity |
| CN104603110B (zh) | 2012-10-18 | 2016-08-31 | 霍夫曼-拉罗奇有限公司 | 作为mGluR5受体活性的调节剂的乙炔基衍生物 |
| WO2014124560A1 (en) | 2013-02-18 | 2014-08-21 | Hua Medicine (Shanghai) Ltd. | Mglur regulators |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| HUE034849T2 (en) | 2013-09-25 | 2018-03-28 | Hoffmann La Roche | Ethinyl derivatives |
| TWI649310B (zh) | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| JP6286577B2 (ja) | 2014-02-25 | 2018-02-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | エチニル誘導体 |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CN107207481B (zh) | 2015-03-19 | 2020-03-03 | 豪夫迈·罗氏有限公司 | 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物 |
| MX374409B (es) | 2015-07-15 | 2025-03-04 | Hoffmann La Roche | Derivados de etinilo como moduladores del receptor de glutamato metabotrópico. |
| US10391998B2 (en) | 2016-11-16 | 2019-08-27 | Ford Global Technologies, Llc | Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness |
-
2017
- 2017-07-12 PL PL17742971T patent/PL3484889T3/pl unknown
- 2017-07-12 WO PCT/EP2017/067495 patent/WO2018015235A1/en not_active Ceased
- 2017-07-12 RU RU2019102757A patent/RU2745068C2/ru active
- 2017-07-12 SI SI201730468T patent/SI3484889T1/sl unknown
- 2017-07-12 PE PE2018003348A patent/PE20190382A1/es unknown
- 2017-07-12 MX MX2019000442A patent/MX376249B/es active IP Right Grant
- 2017-07-12 RS RS20201217A patent/RS60908B1/sr unknown
- 2017-07-12 CA CA3030788A patent/CA3030788A1/en not_active Abandoned
- 2017-07-12 JP JP2019502162A patent/JP6936305B2/ja active Active
- 2017-07-12 DK DK17742971.9T patent/DK3484889T3/da active
- 2017-07-12 MA MA45665A patent/MA45665B1/fr unknown
- 2017-07-12 EP EP17742971.9A patent/EP3484889B1/en active Active
- 2017-07-12 KR KR1020197003025A patent/KR20190026805A/ko not_active Abandoned
- 2017-07-12 AU AU2017299083A patent/AU2017299083B2/en not_active Ceased
- 2017-07-12 BR BR112019000314-2A patent/BR112019000314A2/pt not_active IP Right Cessation
- 2017-07-12 CR CR20190014A patent/CR20190014A/es unknown
- 2017-07-12 CN CN201780044455.5A patent/CN109476671B/zh active Active
- 2017-07-12 ES ES17742971T patent/ES2826389T3/es active Active
- 2017-07-12 SG SG11201811829QA patent/SG11201811829QA/en unknown
- 2017-07-12 HR HRP20201615TT patent/HRP20201615T1/hr unknown
- 2017-07-12 LT LTEP17742971.9T patent/LT3484889T/lt unknown
- 2017-07-12 HU HUE17742971A patent/HUE051006T2/hu unknown
- 2017-07-12 PT PT177429719T patent/PT3484889T/pt unknown
- 2017-07-17 AR ARP170101987A patent/AR109075A1/es unknown
- 2017-07-17 TW TW106123741A patent/TWI729169B/zh not_active IP Right Cessation
-
2018
- 2018-12-19 CO CONC2018/0013824A patent/CO2018013824A2/es unknown
- 2018-12-20 IL IL263884A patent/IL263884A/en active IP Right Grant
-
2019
- 2019-01-07 CL CL2019000045A patent/CL2019000045A1/es unknown
- 2019-01-08 ZA ZA2019/00113A patent/ZA201900113B/en unknown
- 2019-01-16 PH PH12019500119A patent/PH12019500119A1/en unknown
- 2019-01-17 US US16/250,278 patent/US20190144458A1/en not_active Abandoned
-
2020
- 2020-05-01 US US16/865,233 patent/US11242349B2/en active Active
-
2022
- 2022-01-04 US US17/568,530 patent/US12145940B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013545730A5 (ru) | ||
| JP2012521994A5 (ru) | ||
| RU2018103944A (ru) | Производные этинила как модуляторы метаботропного рецептора глутамата | |
| JP2012505836A5 (ru) | ||
| JP2013032389A5 (ru) | ||
| EA201490569A1 (ru) | Полиморфная форма гидрохлорида придопидина | |
| JP2013525444A5 (ru) | ||
| RU2017105353A (ru) | Соединения | |
| RU2010143864A (ru) | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов | |
| CN109982699A (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| JP2017531619A5 (ru) | ||
| EP2607363A4 (en) | CONDENSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | |
| JP2016510326A5 (ru) | ||
| RU2017112308A (ru) | Композиции и способы для лечения бессонницы | |
| JP2019529514A5 (ru) | ||
| JP2016522254A5 (ru) | ||
| JP2016537338A5 (ru) | ||
| RU2019102757A (ru) | Производные этинила | |
| JP2019529460A5 (ru) | ||
| JP2015516419A5 (ru) | ||
| JP2013523740A5 (ru) | ||
| HRP20201187T1 (hr) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| RU2017137960A (ru) | Применение тиаоксосоединений для уменьшения содержания аро сз | |
| JP2018510206A5 (ru) |